Compounds > angiotensin ii
Page last updated: 2024-08-22

angiotensin ii and valyltyrosine

angiotensin ii has been researched along with valyltyrosine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Asada, K; Kawasaki, T; Matsui, T; Osajima, K; Osajima, Y; Seki, E; Yoshida, M1
Kawasaki, T; Matsui, T; Matsumoto, K; Osajima, K; Seki, E; Tamaya, K1
Hayashi, A; Kawasaki, T; Kimoto, K; Matsui, T; Matsumoto, K; Murakami, K; Tamaya, K1
Imamura, M; Kawasaki, T; Kimoto, K; Matsui, T; Matsumoto, K; Oka, H; Osajima, K1
Matsumoto, K; Miyamotq, T; Oka, H; Osajima, K; Tanaka, M; Toshiro, M; Ueno, T1
Morel, N; Smagghe, G; Szust, J; Van Camp, J; Vercruysse, L1

Trials

1 trial(s) available for angiotensin ii and valyltyrosine

ArticleYear
Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects.
    Journal of human hypertension, 2000, Volume: 14, Issue:8

    Topics: Adult; Aldosterone; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Dipeptides; Double-Blind Method; Female; Fishes; Humans; Hydrolysis; Hypertension; Male; Middle Aged; Muscles; Reference Values

2000

Other Studies

5 other study(ies) available for angiotensin ii and valyltyrosine

ArticleYear
Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system.
    Clinical and experimental pharmacology & physiology, 2002, Volume: 29, Issue:3

    Topics: Absorption; Administration, Oral; Adult; Aldosterone; Angiotensin I; Angiotensin II; Antihypertensive Agents; Blood Circulation; Dipeptides; Dose-Response Relationship, Drug; Humans; Male

2002
Depressor effect induced by dipeptide, Val-Tyr, in hypertensive transgenic mice is due, in part, to the suppression of human circulating renin-angiotensin system.
    Clinical and experimental pharmacology & physiology, 2003, Volume: 30, Issue:4

    Topics: Aging; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Dipeptides; Humans; Hypertension; Male; Mice; Mice, Transgenic; Renin-Angiotensin System

2003
Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats.
    Journal of peptide science : an official publication of the European Peptide Society, 2004, Volume: 10, Issue:9

    Topics: Administration, Oral; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Dipeptides; Hypertension; Rats; Rats, Inbred SHR; Tissue Distribution

2004
Antiproliferative action of an angiotensin I-converting enzyme inhibitory peptide, Val-Tyr, via an L-type Ca2+ channel inhibition in cultured vascular smooth muscle cells.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:6

    Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Division; Cells, Cultured; Cytoskeletal Proteins; Dipeptides; Humans; Muscle, Smooth, Vascular; Paxillin; Phosphoproteins; Potassium Channel Blockers; Vasoconstrictor Agents

2005
Antihypertensive mechanism of the dipeptide Val-Tyr in rat aorta.
    Peptides, 2008, Volume: 29, Issue:2

    Topics: Acetylcholine; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta; Dipeptides; Dose-Response Relationship, Drug; Free Radical Scavengers; In Vitro Techniques; Lisinopril; Male; Norepinephrine; Oligopeptides; Potassium Chloride; Rats; Rats, Wistar; Vasoconstriction

2008